Richmond Pharmacology is a centre for excellence for First-In-Human and early phase clinical studies. We reduce drug development timelines using our Adaptive Protocols and efficient Patient Recruitment.
Our sponsors are granted fast international marketing approvals due to our inclusive study design which fulfils the data requirements of global regulators.
As a full service CRO, our expertise spans consultancy and concept development through to final reporting. We work with leading experts in a multitude of therapy areas.
We work with leading genetic engineering organisations, top 10 pharma companies and dynamic biotechs to assess the safety and efficacy of new therapeutics.
By working with us, you will gain a research partner who can expedite your study start up, enable fast decisions and reduce your drug development timelines.
Our business ethos is unique
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology in 2001. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.
Transforming clinical trials to accelerate drug development – Keith Berelowitz
August 23, 2022
Dr Keith Berelowitz, Richmond Pharmacology’s Director of Operations, wrote recently for Pharmaceutical Market Europe where he outlined how innovations in the design and delivery of clinical trials are speeding up the discovery of new therapies for the benefit of patients, sponsors and health systems.